Phase 2 Psoriasis Trial, Recruiting NCT07489885 Sponsor: InventisBio Co., Ltd Condition: Psoriasis
Back to Psoriasis

Phase 2 Psoriasis Trial, Recruiting

NCT07489885
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with plaque psoriasis and have not had any significant flare-ups of their condition for at least 6 months before signing the consent form
  • People whose plaque psoriasis is considered moderate to severe, based on three specific medical measurements: a large enough area of skin affected, a standardised score measuring the severity and coverage of psoriasis (PASI score of 12 or above), and a doctor's overall rating of disease severity (a score of 3 or above out of 5)
  • People whose routine blood and laboratory test results fall within normal ranges

Who may not be able to join:

  • People who have other health conditions or a past medical history that, in the opinion of the trial doctor, could interfere with how the trial assessments are carried out (confirm with trial site for the full list of specific conditions)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 3025195966

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
InventisBio Co., Ltd
Registry
ClinicalTrials.gov
Start date
3 June 2026
Est. completion
1 August 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Improvement in PASI-90

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov